Australian IV Iron Surge: Implications for Oral Supplement Market & Practitioner Channels

Sydney, Australia — 24 May 2024

New research reveals a dramatic increase in intravenous (IV) iron use among Australian women of reproductive age, impacting the broader iron supplementation market. A study covering 2013 to 2024 observed a 17-fold surge in IV iron administration, culminating in one in 20 women receiving the treatment in the most recent year. This rise signifies a notable shift in clinical practice for managing iron deficiency, directly influencing consumer health choices and supplement market dynamics.

The cost implications are substantial. Australian government expenditure on IV iron treatments escalated from AUD$1.1 million in 2013 to AUD$82 million by 2024. While government subsidies cover a portion, clinics frequently charge several hundred dollars per infusion directly to patients, positioning IV iron as a premium, rapid-acting solution. This cost structure and medical endorsement may lead consumers to bypass traditional oral iron supplements, even for less severe deficiencies, perceiving IV as a more effective or efficient route.

The identified demographic for increased IV iron use – women aged 18-50 – is a core consumer segment for oral iron supplements addressing menstrual blood loss, pregnancy, and general fatigue. This medicalisation of iron deficiency treatment could reconfigure market share, particularly for high-dose or quick-absorption oral formulations that compete directly with the perceived benefits of IV administration. Manufacturers must assess current product positioning and explore reformulation or marketing strategies to highlight the efficacy, convenience, and cost-effectiveness of oral options for appropriate cohorts.

This trend also underscores the critical role of healthcare practitioners in directing iron deficiency management. Oral supplement brands must engage more effectively with general practitioners, gynaecologists, and pharmacists to ensure that oral iron remains the first-line treatment for suitable patients. Emphasising evidence-backed efficacy, bioavailability, and tolerability for various oral formats (e.g., liposomal, chelated) will be crucial for maintaining market relevance.

What this means for Australia

Australian supplement manufacturers and brand owners must recalibrate their iron supplement strategies. The 17-fold rise in IV iron use, costing the government AUD$82 million annually, indicates a strong clinical preference shift. This creates competitive pressure for oral supplement sales, particularly in pharmacy and practitioner channels. Brands should focus on differentiated, bioavailable oral iron formats with robust clinical evidence, such as ferrous bisglycinate or liposomal iron, and target practitioner education to reinforce oral iron's role in mild-to-moderate deficiencies. Reformulation windows should assess inclusion of gut-friendly formulations to improve compliance and patient experience. Procurement teams must monitor ferrous salt pricing given potential shifts in demand and supply for oral vs. IV applications.

This trend is being actively addressed by UK manufacturing partners including Supplement Factory.